GS967: Cardiac Late Sodium Current Inhibitor for Arrhythmia Models

Understanding GS967 and Its Role in Cardiac Electrophysiology

Research into cardiac arrhythmias and age-related myopathies increasingly centers on the late sodium current (late INa) as a critical determinant of ventricular repolarization and arrhythmogenesis. GS967 (SKU B5850) from APExBIO is a potent, selective inhibitor of the cardiac late sodium current, with an IC50 of 0.13 μM in ventricular myocytes—making it exceptionally well-suited for dissecting the pathophysiology of arrhythmias and for testing antiarrhythmic strategies in in vitro cardiac electrophysiology workflows. Unlike earlier sodium channel blockers, GS967 offers concentration- and voltage-dependent inhibition with minimal use-dependence, sparing peak sodium current and thereby minimizing off-target effects on conduction (related article).

Key Innovation from the Reference Study

The reference study (Am J Physiol Heart Circ Physiol 326: H1424–H1445, 2024) establishes a mechanistic link between age-related phosphorylation of the cardiac sodium channel Nav1.5 at Ser571, increased late sodium current, and impaired ventricular relaxation. By using genetically engineered mouse models, the authors demonstrate that enhanced late INa prolongs myocardial repolarization and impairs diastolic function, both of which are reversed by pharmacological inhibition of late INa. This finding translates directly into the rationale for deploying late sodium current inhibitors like GS967 in experimental setups: it allows for the isolation and reversal of age- or disease-related electrical dysfunctions, providing a powerful assay endpoint for arrhythmia prevention research.

Step-by-Step Workflow Enhancement with GS967

Integrating GS967 into cardiac electrophysiology experiments offers several advantages for modeling arrhythmogenic mechanisms and testing therapeutic hypotheses. Below is a recommended workflow that leverages the compound’s selectivity and potency:

1. Preparation of Stock Solution: Dissolve GS967 in DMSO at a concentration of 10 mM. Vortex until fully dissolved, as the compound is insoluble in water but highly soluble in DMSO (≥13.35 mg/mL) and ethanol (≥25.52 mg/mL with ultrasonication) (product information).
2. Cell or Tissue Preparation: Isolate ventricular myocytes from young, adult, or aged animal models. For late INa measurements, use whole-cell voltage clamp protocols tailored to the specific age or genotype of the animal, as outlined in the reference study.
3. Compound Application: Dilute GS967 to final working concentrations (e.g., 0.1–1 μM) in perfusion buffer. Apply to cells or perfused tissue for at least 5–10 minutes to achieve steady-state inhibition. Monitor for reduction in late INa amplitude and corresponding action potential duration (APD) shortening.
4. Functional Readouts: Quantify late INa, APD at 90% repolarization (APD90), and arrhythmia incidence. In aged or genetically modified myocytes with elevated late INa, GS967 should produce significant APD shortening and reduction of arrhythmogenic events (complementary study).

Protocol Parameters

• GS967 stock preparation: Dissolve at 10 mM in DMSO; store aliquots at -20°C; avoid repeated freeze-thaw cycles to maintain compound integrity.
• Working concentration in electrophysiology assays: 0.1–1 μM (final), with perfusion time of 5–15 minutes for steady-state current inhibition and action potential stabilization.
• Perfusion buffer composition: Standard Tyrode’s solution (NaCl 140 mM, KCl 5.4 mM, CaCl₂ 1.8 mM, MgCl₂ 1 mM, HEPES 10 mM, Glucose 10 mM; pH 7.4); ensure DMSO content does not exceed 0.1% (v/v) in final solution to avoid solvent effects.

Advanced Applications and Comparative Advantages

GS967’s selectivity for late sodium current over peak current unlocks several unique research opportunities. In in vitro cardiac electrophysiology, it enables precise mapping of late INa contributions to arrhythmogenic triggers, especially in conditions such as heart failure, ischemia, or oxidative stress, where late sodium influx is pathologically increased (extended protocol article). Notably, in isolated rabbit hearts, GS967 abolishes torsades de pointes (TdP) arrhythmias induced by ATX-II or E-4031 and reduces MAPD90 without affecting conduction time, demonstrating both efficacy and cardiac safety (product details).

Comparative studies have shown that while classical sodium channel blockers often suppress both peak and late INa—risking negative inotropy and conduction disturbances—GS967’s minimal use-dependence and voltage-dependent action preserve physiological conduction and contractility. This makes it a superior tool for dissecting the role of late sodium current in arrhythmia prevention research and for screening candidate compounds in preclinical models (application overview).

Troubleshooting and Optimization Tips

• Compound Solubilization: If precipitation is observed upon dilution, ensure GS967 is first dissolved in DMSO and then added slowly to pre-warmed buffer under gentle agitation. For ethanol-based solutions, ultrasonication may be needed for full dissolution.
• Solution Stability: Prepare fresh working solutions for each experiment, as GS967 is not recommended for long-term storage in solution. Store solid aliquots at -20°C and avoid multiple freeze-thaw cycles.
• DMSO Tolerance: Maintain final DMSO concentration ≤0.1% (v/v) in the assay buffer to minimize solvent-induced electrophysiological artifacts.
• Electrophysiology Artifacts: To distinguish late INa from residual peak current, employ voltage protocols with sufficient holding and test potentials (e.g., holding at -120 mV, step to -30 mV), and apply GS967 after establishing baseline for at least 5 minutes. Confirm specificity by washout and/or comparison with alternative late sodium current inhibitors, if available.
• Species Variability: Adjust GS967 concentrations and incubation times based on species and cell type, as sensitivity may vary between mouse, rabbit, and human-derived myocytes.

Interlinking with the Literature Landscape

Multiple recent studies reinforce the translational significance of GS967 in arrhythmia research. For instance, the article "GS967: Cardiac Late Sodium Current Inhibitor in Aging Research" complements the present workflow by providing advanced troubleshooting strategies and highlighting GS967’s role in aging myocardium models. Meanwhile, "Solving Cardiac Electrophysiology Challenges with GS967" offers a step-wise guide to integrating GS967 into diverse electrophysiology platforms, emphasizing reproducibility and sensitivity. Together, these resources create a robust methodological framework for both novice and advanced researchers.

Future Outlook: Implications for Cardiac Arrhythmia Research

The reference study’s demonstration that late sodium current inhibition can reverse key features of the aging cardiac phenotype directly informs the use of GS967 as an essential tool for both mechanistic and translational studies. With the aging population poised to expand significantly in coming decades, the need for precise, scalable, and selective interventions in arrhythmia research has never been greater. GS967—trusted by APExBIO—stands as a benchmark compound for linking molecular channelopathies, such as Nav1.5 Ser571 phosphorylation, to functional arrhythmia endpoints. Future efforts will likely focus on integrating GS967 into high-throughput screening platforms, multi-cellular tissue models, and personalized medicine approaches, further illuminating the path from bench to bedside.